[go: up one dir, main page]

MX2019008621A - Peptidos terapeuticos y neuroprotectores. - Google Patents

Peptidos terapeuticos y neuroprotectores.

Info

Publication number
MX2019008621A
MX2019008621A MX2019008621A MX2019008621A MX2019008621A MX 2019008621 A MX2019008621 A MX 2019008621A MX 2019008621 A MX2019008621 A MX 2019008621A MX 2019008621 A MX2019008621 A MX 2019008621A MX 2019008621 A MX2019008621 A MX 2019008621A
Authority
MX
Mexico
Prior art keywords
retinal
treating
inherited
therapeutic
enhancing
Prior art date
Application number
MX2019008621A
Other languages
English (en)
Inventor
L Karageozian Hampar
Y Park John
H Karageozian Vicken
Original Assignee
Allegro Pharmaceuticals Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allegro Pharmaceuticals Llc filed Critical Allegro Pharmaceuticals Llc
Publication of MX2019008621A publication Critical patent/MX2019008621A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Los péptidos no naturales y sus métodos de uso en seres humanos o animales no humanos pueden causar un efecto tal como: neuroprotección, protección contra o disminución de alteración o daños en los nervios, tratamiento del glaucoma, tratamiento de la degeneración macular relacionada con la edad u otras degeneraciones retinianas hereditarias o adquiridas, mejora de la reparación del tejido retiniano, mejora de la terapia regenerativa de la retina a través de la activación de células inmunes innatas o el tratamiento de la degeneración retiniana hereditaria o adquirida.
MX2019008621A 2017-01-19 2018-01-18 Peptidos terapeuticos y neuroprotectores. MX2019008621A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762448300P 2017-01-19 2017-01-19
US201762500998P 2017-05-03 2017-05-03
PCT/US2018/014287 WO2018136669A2 (en) 2017-01-19 2018-01-18 Therapeutic and neuroprotective peptides

Publications (1)

Publication Number Publication Date
MX2019008621A true MX2019008621A (es) 2020-01-21

Family

ID=62905452

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019008621A MX2019008621A (es) 2017-01-19 2018-01-18 Peptidos terapeuticos y neuroprotectores.

Country Status (12)

Country Link
US (2) US20180207227A1 (es)
EP (1) EP3570867A4 (es)
JP (1) JP7330510B2 (es)
KR (1) KR20190120197A (es)
CN (1) CN110678193A (es)
AU (1) AU2018210241A1 (es)
BR (1) BR112019014843A2 (es)
CA (1) CA3050904A1 (es)
IL (1) IL268169A (es)
MX (1) MX2019008621A (es)
WO (1) WO2018136669A2 (es)
ZA (1) ZA201905372B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11673914B2 (en) 2009-11-10 2023-06-13 Allegro Pharmaceuticals, LLC Peptide therapies for reduction of macular thickening
CN110559422A (zh) 2009-11-10 2019-12-13 急速制药公司 用于抑制细胞粘附至rgd结合位点或引导诊断剂或治疗剂至 rgd结合位点的方法
KR20200022435A (ko) * 2017-06-19 2020-03-03 알레그로 파마슈티칼스, 엘엘씨 펩타이드 조성물 및 관련된 방법
US12454549B2 (en) 2017-06-19 2025-10-28 Jenius Pharma, Llc Treatments for diseases and disorders that involve oxidative stress
CN114173802A (zh) * 2019-07-26 2022-03-11 急速制药有限责任公司 用于治疗非渗出性黄斑变性和其他眼睛病症的肽
US20210275624A1 (en) * 2020-03-06 2021-09-09 Allegro Pharmaceuticals, LLC Treatments for improving or lessening impairment of mitochondrial function
EP4527363A1 (en) 2023-09-22 2025-03-26 OD-OS MacuTherm GmbH Device and method for laser treatment of the retina of an eye with a laser power above the eye safety threshold

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6194415B1 (en) * 1995-06-28 2001-02-27 Allergan Sales, Inc. Method of using (2-imidazolin-2-ylamino) quinoxoalines in treating neural injury
US7510824B2 (en) * 1999-06-02 2009-03-31 Nono Inc. Method of screening peptides useful in treating traumatic injury to the brain or spinal cord
US20070248569A1 (en) * 2003-01-07 2007-10-25 Michal Eisenbach-Schwartz Eye-Drop Vaccine Containing Copolymer 1 for Therapeutic Immunization
US11673914B2 (en) * 2009-11-10 2023-06-13 Allegro Pharmaceuticals, LLC Peptide therapies for reduction of macular thickening
CN110559422A (zh) 2009-11-10 2019-12-13 急速制药公司 用于抑制细胞粘附至rgd结合位点或引导诊断剂或治疗剂至 rgd结合位点的方法
CN104080467B (zh) 2011-05-09 2020-09-15 急速制药公司 整联蛋白受体拮抗剂及其使用方法
WO2017170626A1 (ja) * 2016-03-30 2017-10-05 千寿製薬株式会社 水性液剤
KR20200022435A (ko) * 2017-06-19 2020-03-03 알레그로 파마슈티칼스, 엘엘씨 펩타이드 조성물 및 관련된 방법
CN114173802A (zh) * 2019-07-26 2022-03-11 急速制药有限责任公司 用于治疗非渗出性黄斑变性和其他眼睛病症的肽

Also Published As

Publication number Publication date
US20180207227A1 (en) 2018-07-26
CN110678193A (zh) 2020-01-10
BR112019014843A2 (pt) 2020-04-14
US20210085749A1 (en) 2021-03-25
EP3570867A4 (en) 2020-12-23
WO2018136669A8 (en) 2019-12-26
RU2019126014A (ru) 2021-02-19
ZA201905372B (en) 2021-01-27
JP2020505365A (ja) 2020-02-20
AU2018210241A1 (en) 2019-08-22
JP7330510B2 (ja) 2023-08-22
IL268169A (en) 2019-09-26
KR20190120197A (ko) 2019-10-23
EP3570867A2 (en) 2019-11-27
WO2018136669A3 (en) 2018-09-27
CA3050904A1 (en) 2018-07-26
WO2018136669A2 (en) 2018-07-26
RU2019126014A3 (es) 2021-02-19

Similar Documents

Publication Publication Date Title
MX2019008621A (es) Peptidos terapeuticos y neuroprotectores.
IL272105A (en) Local administration of pharmaceutical agents containing cell-penetrating peptides for use in the treatment of age-related macular degeneration and other eye diseases
MX2017005204A (es) Dispositivos y métodos de estimulación para tratar el ojo seco.
MX2022000754A (es) Composiciones y metodos de uso de nintedanib para tratar enfermedades oculares con neovascularizacion anormal.
PH12017501217A1 (en) Methods of treating retinal diseases
MX387885B (es) Inhibidores de ezh2 para tratar linfomas.
MX372883B (es) Uso de anticuerpos contra claudina 18.2 para el tratamiento de cáncer.
WO2016025635A3 (en) Combination therapy for treating cancer
PH12019500892A1 (en) Treating gastric cancer using combination therapies comprising liposomal irinotecan, oxaliplatin, 5-fluoruracil (and leucovorin)
PH12020551427A1 (en) Epinephrine spray formulations
MX2020008680A (es) Terapia de combinacion con apilimod y agentes glutamatergicos.
BR112016019432A8 (pt) composição terapêutica, kit e seus usos na terapia gênica contra degeneração da retina
HK1253549A1 (zh) Lym-1和lym-2靶向的car细胞免疫疗法
MX2016009306A (es) Reequilibrado inmunologico epicutaneo.
WO2016043874A3 (en) Combination therapy for treating cancer
PH12020551976A1 (en) SELECTIVE TREG STIMULATOR RUR20kD-IL-2 AND RELATED COMPOSITIONS
CY1123501T1 (el) Χρηση ρεσλιζουμαμπης για τη θεραπευτικη αντιμετωπιση μετριου εως σοβαρου ηωσινοφιλικου ασθματος
MY196991A (en) Anti-cd154 antibody having improved binding, functional and safety characteristics and use in human immunotherapy
MX2018004616A (es) Cosmetica qie tiene bacterias probioticas.
MY187167A (en) Medical treatments based on anamorelin
PH12018502161A1 (en) Methods of treatment for cholestatic and fibrotic diseases
PH12017501993A1 (en) Methods of treating epstein-barr-virus-associated lymphoproliferative disorders by t cell therapy
MX379201B (es) Derivados de 3-(carboxietil)-8-amino-2-oxo-1,3-diaza-espiro-[4.5]-decano.
MX2025001445A (es) Anticuerpos monoclonales anti-trkb y metodos de uso
TN2019000112A1 (en) Ophthalmic formulation comprising citicoline carried by liposome for the treatment of glaucoma